39870-05-8

• 常用中文名：1-(嘧啶-4-基)乙酮
• 常用英文名：4-Acetylpyrimidine
• CAS号：39870-05-8
• 分子式：C₆H₆N₂O
• 分子量：122.125
• 发布时间：2018-04-04 08:00:00
• 更新时间：2024-01-09 10:35:45

名称

• 中文名: 1-(嘧啶-4-基)乙酮
• 英文名: 1-pyrimidin-4-ylethanone
• 英文别名: methyl 4-pyrimidyl ketone; Ethanone, 1-(4-pyrimidinyl)-; 1-(Pyrimidin-4-yl)ethanon; Methyl pyrimidin-4-yl ketone; 4-pyrimidyl methyl ketone; methyl 4-pyrimidinyl ketone; 1-(4-Pyrimidinyl)ethanone; 1-pyrimidin-4-yl-ethanone; 1-(pyrimidin-4-yl)ethanone; 4-Acetylpyrimidine

物化性质

• 密度: 1.1±0.1 g/cm3
• 沸点: 224.5±13.0 °C at 760 mmHg
• 分子式: C₆H₆N₂O
• 分子量: 122.125
• 闪点: 92.1±26.3 °C
• 精确质量: 122.048012
• PSA: 42.85000
• LogP: 0.24
• 蒸汽压: 0.1±0.4 mmHg at 25°C
• 折射率: 1.516
• 储存条件: 2-8°C，干燥密封

安全

• 海关编码: 2933599090

合成路线

289-95-2 75-07-0 ~49% 39870-05-8

文献：Dahal, Upendra P.; Jones, Jeffrey P.; Davis, John A.; Rock, Dan A. Drug Metabolism and Disposition, 2011 , vol. 39, # 12 p. 2355 - 2360

676-58-4 497-19-8 42839-04-3 ~% 39870-05-8

文献：SmithKline Corporation Patent: US3932641 A1, 1976 ;

917-64-6 42839-04-3 ~37% 39870-05-8

文献：Cibulka, Radek; Hampl, Frantisek; Martinu, Tomas; Mazac, Jiri; Totevova, Sonja; Liska, Frantisek Collection of Czechoslovak Chemical Communications, 1999 , vol. 64, # 7 p. 1159 - 1179

28648-80-8 ~66% 39870-05-8

文献：Naumenko, I. I.; Mikhaleva, M. A.; Mamaev, V. P. Chemistry of Heterocyclic Compounds (New York, NY, United States), 1981 , vol. 17, # 7 p. 710 - 714 Khimiya Geterotsiklicheskikh Soedinenii, 1981 , # 7 p. 958 - 962

1073-65-0 ~% 39870-05-8

文献：Naumenko, I. I.; Mikhaleva, M. A.; Mamaev, V. P. Chemistry of Heterocyclic Compounds (New York, NY, United States), 1981 , vol. 17, # 7 p. 710 - 714 Khimiya Geterotsiklicheskikh Soedinenii, 1981 , # 7 p. 958 - 962

上下游产品

上游产品  8
289-95-2 75-07-0 676-58-4 497-19-8
42839-04-3 917-64-6 28648-80-8 1073-65-0
下游产品  1
845267-57-4

海关

海关编码	2933599090
中文概述	2933599090. 其他结构上有嘧啶环的化合物(包括其他结构上有哌嗪环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期
Summary	2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%